The SHIMMER study is designed to evaluate the safety and effectiveness of the study drug CT1812 in adults with mild to moderate Dementia with Lewy Bodies (DLB). The purpose of this study is to learn how well you or your loved one tolerate(s) a once-a-day oral dose of CT1812. This research study will take place at multiple locations in the US. Qualified participants will be in this study for approximately 8 months.
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Andrea Bozoki
Neurology
Clinical or Medical
Interventional
Brain, Head, Nervous System
Mental and Emotional Health
22-0768
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
